Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3629409 A
Publication typeGrant
Publication dateDec 21, 1971
Filing dateApr 29, 1969
Priority dateApr 29, 1969
Publication numberUS 3629409 A, US 3629409A, US-A-3629409, US3629409 A, US3629409A
InventorsRoy Gregory
Original AssigneeRoy Gregory
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Pain removing composition and process for preparing same
US 3629409 A
Images(3)
Previous page
Next page
Description  (OCR text may contain errors)

United States Patent 3,629,409 PAIN REMOVING COMPOSITION AND PROCESS FOR PREPARING SAME Roy Gregory, 1130 N. 14th St, Lafayette, Ind. 47904 No Drawing. Filed Apr. 29, 1969, Ser. No. 820,311 Int. Cl. A61k 27/00 U.S. Cl. 424195 2 Claims ABSTRACT OF THE DISCLOSURE Pain removing composition for external use on warm blooded animals. The composition is made from critical proportions of acetic acid, urea, ammonium hydroxide, glycerol, plastiquinone A and Water. A binder is used to tie the components together. The binder contains lanolin, stearic acid, water, triethanolamine and mineral oil. When rubbed on an external part of an afltected area of a warm blooded animal, pain is removed in a short period of time.

BACKGROUND OF THE INVENTION Field of the invention This invention is concerned with a medicinal product of the pain remover type. More specifically this invention is concerned with an external pain remover for use on Warm blooded animals. The pain remover of this invention is particularly suited for use on humans.

Description of the prior art Pain removing compositions for external use are generally known in the prior art. Most of the prior art compositions contain ingredients Which when applied to the surface of a warm blooded animal causes the area to feel hot or cold. These compositions generally change the flow rate of blood to the alfected area. Common components in these prior art compositions are capiscum, chloroform, menthol, methyl, salicylate, turpentine, camphor, oil of mustard, aspirin, narcotics, etc.

While the composition and method of the subject invention is similar to the above described prior art in that it is applied externally, its action is totally different because it does not draw more blood to the area in question or change the flow rate of blood in any manner.

Other prior art methods include massage, light rays, swirl baths, ultrasonic sound waves, etc. While these additional prior art methods bring some relief, they are disadavntageous in that they are time consuming and they are expensive.

Generally, it could be said that the prior art compositions and methods are slow to act and are only capable of rendering temporary relief. In contrast the present invention functions in a short period of time and it is capable of rendering relief which lasts for an extended period of time. It may be of interest to note that this invention also removes the pain and swelling due to injury or pain due to bursitis without any sensation that the pain and swelling is being removed.

SUMMARY OF THE INVENTION The invention is concerned with a pain removing composition for external use on Warm blooded animals, a method of removing pain, and a method for the manufacture of the composition. The composition is made from critical percentages of acetic acid, urea, ammonium hydroxide, glycerol, plastiquinone A, a binder and Water.

DESCRIPTION OF THE PREFERRED EMBODIMENT The pain remover of this invention is for external use on warm blooded animals. The composition of this inven- Patented Dec. 21, 1971 TABLE I Percent Acetic acid (100%) 290-4 Urea (U.S.P.) 3.75-5 Ammonium hydroxide (26%) 4.5-6 Glycerol (U.S.P.) 3-6 10% plastiquinone A by weight dissolved in an aliphatic solvent which is not harmful when applied externally 4-90 Binder 2 1-2 Water Balance Plastiquinone A is produced by extracting finely divided fresh spinach chloroplast with an aliphatic solvent for 12 hours; heptane is the preferred solvent. A 93% yield is achieved. The resulting product contains 10 percent plastiquinone A in heptane, if heptane is used; and it is equivalent to 10 percent plastiquinone and heptane. Plastiquinone A has a structure in accordance with Formula I.

Formula I 2 The binder for use in this invention is prepared by mixing together at about 200 F. by volume about 16 percent lanolin. about 4 percent stearic acid, about 4 percent Water and about 1 percent triethanolamine, upon cooling about 11 percent mineratl oil is added along with suificient water to make percen A preferred composition in accordance with this invention is set forth in Table II.

TABLE II Percent Acetic acid (100%) 3.33 Urea (U.S.P.) 4.18 Ammonium hydroxide (26%) 5.00 Glycerol (U.S.P.) 3.33 10% plastiquinone A 1 in heptane 4.16 Binder 1 2.00 Water 78.00

1 As described for Table I.

The composition of this invention is generally prepared by diluting the acetic acid component with a small amount of water. To this diluted acetic acid is added the urea, which dissolves after shaking for a short period of time. The ammonium hydroxide is then added and then the glycerol. The glycerol disperses with vigorous agitation. The remainder of the water is added to produce a composite system.

The resulting composite system is not compatable with the plastiquinone A Which is dissolved in heptane. Accordingly, the binder as described above is added to the plastiquinone .A component and combined therewith with vigorous agitation. When the plastiquinone A component is combined with the binder the above described composite system is added thereto, with mixing a gel type final product results.

The invention has a high concentration of each component in a small amount of solvent. This arrangement is advantageous because it does not allow each component to combine with other components completely, leaving some 4 acids by a factor of two, this reduction quickly releases this inhibition. Beginning 5 to minutes after the shift down in amino acid supply, a marked depression of the enzyme concerned with the biosynthesis of the restricted of each in a free or uncombined state. The free or un- 5 amino acid occurs as a result of a reduced intracellular combined molecules are necessary to react with the organic concentration of a repressing derivative of the amino acid. acids in the pain affected muscles to change these organic A near total repression of many catabolic enzymes begins acids into products which the natural body metabolism Within a few minutes of the amino acid shift down. The can assimilate. rapidity of response indicates this occurs independently of In addition to removing pain the subject composition 10 y long term affect of amino acid restriction such as is useful as a means of locating the exa t point of injury, reduced enzyme level. Protein synthesis and biosynthetic For example, when an entire arm and shoulder area hurts, enzyme repression require the interaction of the amino a doctor cannot find the exact point of injury. Using this acid With the same specific aminoacyl synthetase. invention, a doctor can pin-point the exact point of injury This invention has the ability to reduce an amino acid in 45 minutes. The point of injury itself will remain tender supply, inhibit an enzyme, unblock their biosynthetic pathto the touch, The doctor can then proceed with proper way, regulate their accumulation. Increase protein syntreatment to a speedy recovery. This is to be contrasted th sis aus th se acids to be removed by natural body with the r ent m th d l d b d t hi h i metabolism. Observation has shown that active acetate to immobilize the arm and shoulder in a plaster cast and identified 110W as acetyl Coenzyme A is involved in y administer pain pills for relief. Sprains are immobilized 2O thesis of fatty acids- Coenzyme A acts as a Carrier not and are soaked in hot packs or ice packs to reduce pain y for acfitYl but for other acfyl p The urea H1016- and swelling, Th present i ti makes these cule reacts with these various acids with the help of e d r unnecessary ammonia and acetyl to change these acids into amines.

The composition of this invention functions by aiding in The s yF acts a hydrogen, an y y acceptorthe rapid assimilation of the organic acids which are con- Plashqulhohe A aftlvates coehlyme Q- centrated in the affected area and are responsible for the Coenzyme Q 15 located and locahlation Within h Sensation of pain, llpoprotein membrane of system of cells. Its activity is P i caused b injury i d mainly t a hi h eoncennecessary for proper functioning of cells. Pain due to intration of oxalic, lactic and amino acids that radiate out- J y lmtahoh 111 111115016 (1116 i0 u s tis Causes this d f i t f i j Thi i ti ill act on enzyme to become dormant. The activity and function of and react with these pain causing acids in the muscle CoehYyme Q is hecfissflfy in The stringent 66118 to return changing th id i t -h f l, i f l dthese cells to normal structure and function. Plastiquinone ucts which the body metabolism can assimilate and move actlvate coehlyme Q and p it Workihg- Plasout very quickly. The oxalic and lactic acids are quickly tiquinone A acts as an electron transport system to transchanged by the subject composition into amines and are P energy through the cells farther y then next to li i d i h hi group ad acent to each cell. A pool of quinone between the Likewise, the Composition f this invention causes an two sites transfers energy from the sites where electron amino acid to inhibit the activity of one of the early flow occurs to thesite where energy 15 used. Plastiquinone enzymes in its pathway. It quickly releases this inhibitor, 40 A undergoes rapld oxldatlon and reductlon during h restricts an oversupply of amino acids, unblocks their bio- .3 z p Coenzyme Q undefrgoei rap 1d synthetic pathway and regulates their accumulation. 2;: 323 i q t ugllateral Finally, the subject composition increases protein synsult of this i g i g z j fi d s a thesis allowing these acids to move out of affected area return p SW mg Oes no f g body a b f The following examples will illustrate the subject innluryl ue g fi 5 causes 3 up 0 s vention. These examples are given for the purpose of ilmuse es W S 0W5 down P synthesls cimslflg lustration and not for purposes of limiting this invention. a p h of the 19 ammo aclds each of Yvhlch The data for Examples 1 to 46 is listed in Table III. In Shuts Its OWH h y f Pathway h thhshontrlhutes these examples the specified dosage was rubbed externally to a build up of intermediary catabolites which are co- 50 on the affected area f the body It can be Seen from repressors of catabolic enzymes. Amino acids have the these examples that in a short period of time the pain ability to 1nh1b1t the activity of one of the early enzymes in the affected area was removed and the relief lasted in its biosynthetic pathway. Reduce the supply of amino for an extended period.

TABLE III Length Time to Length of time pain of time Number pain Dosage, removal, present, of appli- Side removed Name Example Pain due togo ml. Sex minutes years cations efieets months Comments JW 1 Bursitis 50 1-3 M 30 10 1 None 6 Could not raise arm above shoulderafter treatment free movement, no pain. 2 43 1-3 M 40 8 3 Do. 3 38 1-3 M 45 3 6 D0. 4 52 1-5 M 45 10 8 Do.

rheumatism. 5 Tendonitns 55 1-5 M 45 5 2-6 Legs and heel.

rheumatism. 6 Rheumatism 45 1-5 M 30 3 6 Shoulder. 7 Tendonitus 58 M 15-30 20 1-3 Shoulder arms.

bursitis. 8 Arthritis 60 10 F 45 6 10 Arms,legs.

rhematism. 9 Rhernatism 51 10 F 45 5 10 Upperback. 10 do 60 10 F 45 10 5 Hips and legs. 11 Rheumatism 57 (2) F 40 10 2-1 Upperback and arms.

arthritis.

What is claimed is:

1. A process for the manufacture of a pain removing composition which comprises the steps of dissolving from about 3.75 to about 5 percent urea in from about 2.9 to about 4 percent of 100 percent acetic acid; adding thereto from about 4.5 to about 6 percent of 26 percent ammonium hydroxide; adding thereto from about 3 to about 6 percent glycerol, adding thereto from about 4 to about 90 percent of a solution of plastiquinone A in heptane; adding thereto from about 1 to about 2 percent of a binder which is prepared by mixing together at about 200 F. by volume about 16 percent lanolin, about 4 percent stearic acid, about 4 percent water and about 1 percent triethanolamine and upon cooling adding thereto about 11 percent mineral oil and additional water to make 100 percent; and adding sufficient water to make 100 P rcent.

2. The pain removing composition which is produced by the process of claim 1.

References Cited Chem. Abst., 55, 21276 G (1961).

STANLEY J. FRIEDMAN, Primary Examiner

Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US5032400 *Nov 2, 1989Jul 16, 1991Erie LaboratoriesShark liver oil and garlic oil topical analgesic
US5889062 *Mar 24, 1995Mar 30, 1999Beiersdorf AgUbiquinones
WO2003004038A1 *Jul 2, 2002Jan 16, 2003Pando Hector MendezTopically-applied composition based on ammonium hydroxide
Classifications
U.S. Classification514/690
International ClassificationA61K33/02, A61K47/00, A61K9/00
Cooperative ClassificationA61K33/02, A61K9/0014
European ClassificationA61K33/02, A61K9/00M3